Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
  • C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
  • C07C35/37—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with a hydroxy group on a condensed system having three rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/06—Antibacterial agents for tuberculosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
  • C07C33/38—Alcohols containing six-membered aromatic rings and other rings and having unsaturation outside the aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
  • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
  • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
  • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
  • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
  • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
  • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
  • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/18—Nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/38—Nitrogen atoms
  • C07D277/44—Acylated amino or imino radicals
  • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
  • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
  • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
  • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D498/08—Bridged systems

Definitions

• the invention relates to compounds and to cell death, in particular through necrosis and necroptosis, and regulation thereof by small molecules.
• necrotic and/or necrotic pathways In many diseases, cell death is mediated through apoptotic and/or necrotic pathways. While much is known about the mechanisms of action that control apoptosis, control of necrosis is not as well understood. Understanding the mechanisms regulating both necrosis and apoptosis in cells is essential to being able to treat conditions, such as neurodegenerative diseases, stroke, coronary heart disease, kidney disease, and liver disease. A thorough understanding of necrotic and apoptotic cell death pathways is also crucial to treating AIDS and the conditions associated with AIDS, such as retinal necrosis.
• Cell death has traditionally been categorized as either apoptotic or necrotic based on morphological characteristics (Wyllie et al., Int. Rev. Cytol. 68: 251 (1980)). These two modes of cell death were also initially thought to occur via regulated (caspase-dependent) and non-regulated processes, respectively. More recent studies, however, demonstrate that the underlying cell death mechanisms resulting in these two phenotypes are much more complicated and, under some circumstances, interrelated. Furthermore, conditions that lead to necrosis can occur by either regulated caspase-independent or non-regulated processes.
• necroptosis One regulated caspase-independent cell death pathway with morphological features resembling necrosis, called necroptosis, has recently been described (Degterev et al., Nat. Chem. Biol. 1:112 (2005)). This manner of cell death can be initiated with various stimuli (e.g., TNF- ⁇ and Fas ligand) and in an array of cell types (e.g., monocytes, fibroblasts, lymphocytes, macrophages, epithelial cells and neurons).
• stimuli e.g., TNF- ⁇ and Fas ligand
• Necroptosis may represent a significant contributor to and, in some cases, predominant mode of cellular demise under pathological conditions involving excessive cell stress, rapid energy loss, and massive oxidative species generation, where the highly energy-dependent apoptosis process is not operative.
• necrostatins for anti-necroptosis therapeutics.
• the discovery of compounds that prevent caspase-independent cell death would also provide useful therapeutic agents for treating or preventing conditions in which necrosis occurs. These compounds and methods would be particularly useful for the treatment of neurodegenerative diseases, ischemic brain and heart injuries, and head trauma.
• the invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF- ⁇ ) induced necroptosis.
• TNF- ⁇ tumor necrosis factor alpha
• the invention further features pharmaceutical compositions featuring necrostatins.
• the compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.
• the invention features a compound having a structure according to the following formula:
• each R H1 , R H2 , R H3 , R H4 , R H5 , R H10 , R H17 , X H2 , Z H1 , Z H2 , and n is as defined for Formula (I),
• X H2 is selected, independently, from O, S, or NR H9 ;
• each R H1 , R H2 , R H3 , R H4 , and R H5 is selected, independently from H, halogen, cyano, nitro, azido, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —C( ⁇ O)R H12 , —C( ⁇ O)OR H12 , —C( ⁇ O)NR H12 R H13 , —C( ⁇ S)R H12 , —C( ⁇ S)NR H12 R H13 , —C( ⁇ NR H14 )R H12 , —C( ⁇ NR H14 )NR H12 R H13 , or —[Z H1 —(CR H15 R H16 ) n - ⁇ C( ⁇ X H2 ) ⁇
• each Z H1 and Z H2 is selected, independently, from a single bond, O, S, or NR H11 ;
• each R H9 , R H10 , R H11 , R H12 , R H13 , R H14 , R H15 , R H16 , and R H17 is selected, independently from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;
• n is an integer between 0-6;
• o 0 or 1
• R H1 is H
• R H2 is H or CO 2 Me
• R H3 is H
• R H4 is unsubstituted phenyl or phenyl substituted with 1, 2, or 3 substituents selected from methoxy, chloro, or fluoro
• R H5 is CN
• R H10 is H
• Z H1 is S
• n is 1
• X H2 is O
• Z H2 is NH
• R H17 is not H, methyl, methoxy, unsubstituted 2-thiazolyl, unsubstituted phenyl, 4-methoxyphenyl, 4-methylphenyl, 2-ethoxyphenyl, 4-isopropylphenyl, 4-fluorophenyl, or 2,4,6-trimethylphenyl, or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
• the compound has a structure according to Formula (I-B)
• each R H1 and R H3 is selected, independently, from H, halogen, cyano, nitro, azido, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —C( ⁇ O)R H12 , —C( ⁇ O)OR H12 , or —C( ⁇ O)NR H12 R H13 , or R H1 and R H3 combine to form a carbon-carbon double bond;
• each R H4 and R H17 is selected, independently, from optionally substituted aryl or optionally substituted heteroaryl;
• R H5 is selected from H, CN, —C( ⁇ O)OR H12 , or —C( ⁇ O)NR H12 R H13 ;
• each R H10 , R H11 , R H12 , and R H13 is selected from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;
• Z H1 is selected from a single bond or S
• Z H2 is selected from a single bond or NR H11 ;
• X H2 is O or S
• the compound has the following structure:
• R H1 and R H3 are H.
• R H5 is CN
• R H10 is H.
• Z H1 is S.
• Z H2 is NH
• R H4 is unsubstituted phenyl or phenyl having 1, 2, 3, 4, or 5 substituents.
• the phenyl includes 1, 2, or 3 substituents selected from F, Cl, or OR H18 , where each R H18 is, independently, selected from H or optionally substituted C 1-6 alkyl.
• the phenyl is 2-fluorophenyl, 2-chlorophenyl, 4-fluorophenyl, 4-chlorophenyl, 2-methoxyphenyl, 3,4,5-trimethoxyphenyl, or 3,4-dimethoxyphenyl.
• R H17 is optionally substituted heteroaryl.
• heteroaryl selected from furan, thiophene, pyrrole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,2,3-oxadiazole or 1,2,5-oxadiazole, oxazole, benzoxazole, isoxazole, isothiazole, pyrazole, thiazole, benzthiazole, 1,2,4-triazole, 1,2,3-triazole, benzotriazole, pyridine, pyrimidine, pyrazines, quinoline, isoquinoline, purine, pyrazine, pteridine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, indole, 1,2,4,5-tetrazine, benzo[b]thiophene, benzo[c]thiophene, benzofuran, isobenzofuran, and
• the invention features a compound having a structure according to the following formula
• each R A1 , R A3 , and R A4 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R A1 and R A4 combine to form a carbon-carbon double bond;
• G A2 is absent or —(CR A11 R A12 ) n —;
• X A3 is absent or is O, S, or NR A8 ;
• each R A8 and R A13 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —COR A14 , —CO 2 R A14 , or —CONR A14 R A15 ;
• each R A9 , R A10 , R A11 , and R A12 is selected, independently, from H, halogen, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each R A7 , R A14 and R A15 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; and
• each m and n is, independently, 1, 2, or 3;
• R A1 and R A4 are H and the other is selected from H or CO 2 Et, and R A3 is unsubstituted phenyl
• G A2 -X A3 —R A7 is not NHC 6 H 5 , NH(p-C 6 H 4 F), NH(p-C 6 H 4 OH), NH(p-C 6 H 4 OMe), NH(3-OH-4-Cl—C 6 H 4 ), —CH 2 (O-p-C 6 H 4 Me), —CH 2 (4-ethylpiperazinyl), —CH 2 S(2-phenyltetrazolyl), —CH 2 S(4-chlorophenyl), —CH 2 S(2-benzothiazolyl), —CH 2 S(2-(N-methylimidazolye), —CH 2 S(4,6-dimethylquinazolinyl), adamantyl, or optionally substituted oxiranyl; and
• R A1 and R A4 are each H and R A3 is 4-methoxyphenyl, G A2 -X A3 —R A7 is not optionally substituted oxiranyl;
• R A1 and R A4 are H.
• R A3 is unsubstituted phenyl.
• R A3 is phenyl having 1, 2, 3, 4, or 5 substituents.
• G A2 is absent.
• X A3 is absent and R A7 is optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• X A3 is NR A8 and R A7 is optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• G A2 is CH 2 .
• X A3 is S and R A7 is optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• X A3 is absent and R A7 is optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• the invention features compounds according to the following formula
• each R A1 , R A2 , R A4 , and R A6 is selected, independently, from H, —C( ⁇ O)—X A3 —R A7 , optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R A1 and R A4 combine to form a carbon-carbon double bond;
• each X A3 is, independently, absent, —O—, or —NR A8 —,
• each R A8 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —COR A14 , —CO 2 R A14 , or —CONR A14 R A15 ;
• each R A7 , R A14 and R A15 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; and
• R A1 is H, R A4 is H or CO 2 Et, R A2 is unsubstituted phenyl, R A6 is not —C( ⁇ O)-(unsubstituted phenyl) or —C( ⁇ O)-(4-methylphenyl);
• R A1 is H
• R A4 is —C( ⁇ O)-(unsubstituted phenyl)
• R A2 is 4-chlorophenyl
• R A6 is not CO 2 Et;
• R A5 is H; each R A1 , R A2 , R A4 , and R A6 is selected, independently, from H, optionally substituted aryl, optionally substituted heteroaryl, —C( ⁇ O)—X A3 —R A7 , or R A1 and R A4 combine to form a carbon-carbon double bond; each R A7 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
• each X A3 is, independently, absent, —O—, or —NR A8 —,
• R A1 and R A4 combine to form a carbon-carbon double bond.
• R A6 is optionally substituted aryl or optionally substituted heteroaryl.
• R A6 is a phenyl group having a substituent at the 4-position.
• R A1 and R A4 are each H, R A2 is optionally substituted aryl or optionally substituted heteroaryl, and R A6 is —C( ⁇ O)—X A3 —R A7 .
• R A2 is unsubstituted phenyl.
• the invention features a compound having a structure according to the following formula:
• R B1 is selected from H, optionally substituted C 1-6 alkyl, —C( ⁇ O)R B18 , —C( ⁇ O)OR B18 , or —C( ⁇ O)NR B18 R B19 ;
• R B2 is selected from H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, or optionally substituted C 2-6 alkynyl;
• each R B3 and R B4 is selected, independently from H, optionally substituted C 1-6 alkyl, or R B3 and R B4 combine to form a bridging group having the structure —(CH 2 ) n —(CR B13 ⁇ CR B14 ) o —(CH 2 ) p —;
• each n, o, and p is, independently, 0 or 1;
• each R B5 , R B6 , R B7 , R B8 , R B9 , R B10 , R B11 , and R B12 is selected, independently, from H, halogen, —CN, —NO 2 , —N 3 , —R B13 , —OR B13 , —SR B13 , —NR B13 R B14 , —C( ⁇ O)R B15 , —C( ⁇ O)OR B15 , —C( ⁇ O)NR B15 R B16 , —OC( ⁇ O)R B15 , —OC( ⁇ O)OR B15 , —OC( ⁇ O)NR B15 R B16 , —NR B15 C( ⁇ O)R B15 , —NR B15 C( ⁇ O)OR B16 , —NR B15 C( ⁇ O)NR B16 R B17 , —C( ⁇ S)R B15 , —C( ⁇ S)NR B15 R B16 , —
• each R B13 and R B14 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —C( ⁇ O)R B18 , —C( ⁇ O)OR B18 , or —C( ⁇ O)NR B18 R B19 ,
• each R B15 , R B16 , R B17 , R B18 , and R B19 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R B1 is not H or CH 3 when R B5 , R B6 , R B7 , R B8 , R B9 , R B10 , R B11 , and R B12 are each H
• R B2 is ethyl, ethenyl, 2-haloethenyl, ethynyl, haloethynyl, propynyl, or —C ⁇ C—C(OH)(CH 3 ) 2
• R B3 and R B4 are each H or combine to form a bond, —CH 2 CH 2 — or —CH ⁇ CH—;
• R B1 is not H when R B5 , R B6 , R B7 , R B8 , R B10 , and R B11 are each H, at least one of R B9 or R B12 is fluoro, R B2 is ethynyl, and when R B3 and R B4 combine to form —CH 2 CH 2 —;
• R B1 is not H when R B5 , R B7 , R B9 , and R B11 are H and one or two of R B6 , R B8 , R B10 , and R B12 is halogen, nitro, or methyl;
• R B1 is H.
• R B2 is C 1-3 alkyl.
• R B2 is C 1-3 alkenyl.
• R B2 is ethynyl
• R B3 and R B4 are each H.
• the compound has the following structure
• R B2 is ethyl, ethenyl, or ethynyl and each R B9 , R B10 , R B11 , and R B12 is selected, independently, from H and halogen, or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
• R B10 or R B12 is fluoro.
• the compound has the following structure:
• R B2 is ethyl, ethenyl, or ethynyl and each R B9 , R B10 , R B11 , and R B12 is selected, independently, from H and halogen, or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof.
• the invention features a structure according to the following formula
• each R C1 , R C2 , and R C3 is selected, independently, from H, optionally substituted C 1-6 alkyl, —Y—R C7 , or R C1 and R C2 combine to form a ( ⁇ O) or a ( ⁇ S) group, or R C1 and R C3 combine to form a carbon-nitrogen double bond;
• R C4 is selected from H, halogen, —CN, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or —C( ⁇ O)ZR C8 ,
• each R C5 and R C6 is selected, independently, from H, optionally substituted C 1-6 alkyl, or R C5 and R C6 combine to form an optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each R C7 , R C8 , R C9 , R C10 , R C11 , and R C12 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• X is —CR C11 ⁇ CR C12 —, O, S, or NR C9 ;
• Y is, independently, a single bond, (CR C8 R C9 ) n , O, S, or NR C10 ;
• Z is a single bond, O, S, or NR C10 ;
• n is an integer between 0-4;
• R C1 and R C2 combine to form a ( ⁇ O) group
• R C4 is H
• R C5 and R C6 combine to form unsubstituted cyclopentyl
• R C3 is not —CH 2 —R C7 , where R C7 is unsubstituted phenyl, unsubstituted naphthyl, unsubstituted 8-quinolyl, unsubstituted 2-oxoquinolyl, or phenyl having 1 or 2 substituents selected from F, OMe, Me, CN, or Cl; and
• R C1 and R C2 combine to form a ( ⁇ O) group
• R C4 is H
• R C5 and R C6 are each CH 3
• R C3 is not —CH 2 —R C7 , where R C7 is unsubstituted phenyl
• R C1 and R C2 combine to form a ( ⁇ O) group
• R C4 is H
• R C5 and R C6 are H
• R C3 is not —CH 2 (4-halophenyl);
• each R C5 and R C6 is optionally substituted C 1-6 alkyl.
• the compound has a structure according to the following formula:
• X, R C1 , R C2 , R C3 , and R C4 are as defined for Formula (IV) and n is an integer between 0-3,
• R C1 and R C2 combine to form a ( ⁇ O) group.
• X is S.
• n 1
• R C3 is —Y—R C7 .
• R C3 is —(CH 2 )-(optionally substituted aryl).
• the invention features a compound having a structure according to the following formula
• each Y D1 and Y D2 is selected, independently, from —C( ⁇ O)— or —S( ⁇ O) 2 —;
• A is phenyl having 0, 1, 2, 3, or 4 additional substituents
• R D2 and R D3 are selected, independently from H, halogen, CN, NC, N 3 , NO 2 , —COR D13 , —CO 2 R D13 , —CONR D13 R D14 , optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each R D5 , R D9 , R D10 , R D13 , and R D14 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R D9 and R D10 combine to form a heterocyclyl; and
• R D2 , R D3 , and R D5 are H, Y D1 is —(C ⁇ O)—, Y D2 is —(SO 2 )—, and R D9 and R D10 are each ethyl or R D9 is methyl and R D10 is CH 2 (2-tetrahydrofuran), and A is phenyl having 0 additional substituents, Y D1 and Y D2 are not para to each other,
• Y D1 and Y D2 are ortho or meta to each other.
• Y D1 and Y D2 are para to each other.
• the compound has a structure according to the following formula
• each R D2 , R D3 , R D17 , R D18 , R D19 , and R D20 is selected, independently from H, halogen, CN, NC, N 3 , NO 2 , —COR D13 , —CO 2 R D13 , —CONR D13 R D14 , optionally substituted C 1-6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; and
• each R D9 and R D10 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, or optionally substituted aryl, or R D9 and R D10 combine to form a heterocyclyl;
• R D17 , R D18 , R D19 , and R D20 are H.
• R D2 and R D3 are H.
• R D9 and R D10 are each optionally substituted C 1-6 alkyl.
• the invention features a compound having a structure according to
• each Z E2 and Z E3 is selected, independently, from a single bond, —(CR E6 R E7 ) n —, —C( ⁇ O)—, or R E1 and Z E2 —R E2 combine to form a double bond;
• each R E1 , R E2 , and R E4 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R E3 is selected from optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each R E6 and R E7 is selected, independently, from H or optionally substituted C 1-6 alkyl
• each n is an integer between 1-6;
• R E1 and R E4 are H, Z E2 and Z E3 are each CH 2 , and R E2 is unsubstituted 3-indolyl, R E3 is not 4-chlorophenyl or CH 2 CH 2 O(p-C 6 H 4 F),
• the compound has a structure according to
• R E3 is optionally substituted aryl or optionally substituted heteroaryl
• R 9 is H, halogen, CN, NO 2 , OR 13 , NR 13 R 14 , COR 15 , CO 2 R 15 , or optionally substituted C 1-6 alkyl;
• each R 13 and R 14 is selected, independently, from H, COR 16 , CO 2 R 16 , optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and,
• each R 15 and R 16 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R E3 is optionally substituted aryl.
• R E3 is unsubstituted C 3-10 cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl.
• R E3 is substituted C 3-10 cycloalkyl, substituted heterocyclyl, substituted aryl, or substituted heteroaryl.
• the substituted C 3-10 cycloalkyl, substituted heterocyclyl, substituted aryl, or substituted heteroaryl includes 1, 2, 3, 4, or 5 substituents selected, independently, from the group consisting of: C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N 3 , —OR′, —NR′C( ⁇ O)R′′, —C( ⁇ O)NRR′, —NRR′, —OC( ⁇ O)NR′R′′, —NRC( ⁇ O)OR′, —OH, and —NC), wherein each R or R′ is selected, independently, from H, C 1-6 alkyl, C 2-6 alkenyl, C 2
• R E3 is substituted aryl or substituted heteroaryl. In some embodiments, R E3 is substituted phenyl. In some embodiments, the substituted phenyl is substituted with at least one halogen. In other embodiments, the substituted phenyl is substituted with 1, 2, 3, 4, or 5 substituents selected, independently, from the group consisting of: C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, —N 3 , —OR′, —NR′C( ⁇ O)R′′, —C(O)NRR′, —NRR′, —OC( ⁇ O)NR′R′′, —NRC( ⁇ O)OR′, —OH, and —NC), wherein each R or R′ is selected, independently, from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alky
• the stereocenter marked by the asterisk in the compound of Formula (VI) has the (R)-configuration. In other embodiments, the stereocenter marked by the asterisk has the (S)-configuration.
• —Z E3 and R E3 does not include substituents selected from the group consisting of: halogen (e.g., F, Cl, Br, or I); nitro (—NO 2 ), cyano (—CN), acyloxy(—OC( ⁇ O)R′), acyl (—C( ⁇ O)R′), carboxylic acid (—CO 2 H), carboxylic ester (—CO 2 R′), sulfonate (—S( ⁇ O) 2 OR), sulfonamide (—S( ⁇ O) 2 NRR′ or —NRS( ⁇ O) 2 R′), or sulfonyl (—S( ⁇ O) 2 R), where each R or R′ is selected, independently, from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, as described herein.
• halogen e.g., F, Cl, Br, or I
• the invention features a compound having a structure according to the following formula,
• Z F1 is selected from a single bond, —(CH 2 )—, —C( ⁇ O)—, or —S( ⁇ O) 2 —;
• R F1 is selected from H, OR F14 , optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R F2 and R F4 are each H, or R F2 and R F4 combine to form a carbon-carbon double bond;
• each R F6 , R F7 , R F8 , and R F9 is selected, independently, from H, halogen, CN, NC, N 3 , NO 2 , OR F12 , SR F12 , NR F12 R F13 , —COR F12 , —CO 2 F12 , —CONR F12 R F13 , optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
• each R F12 , R F13 , and R F14 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
• R F1 is not -(unsubstituted 1,4-benzodioxane) or —CH 2 —O-(unsubstituted phenyl), or —CH(CH 3 )O(o-tolyl);
• R F2 and R F4 are each H.
• R F6 , R F7 , R F8 , and R F9 are H.
• Z F1 is —C( ⁇ O)—.
• R F1 is optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• the invention features a compound having a structure according to the following formula
• each R G1 , R G2 , R G5 , and R G6 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R G1 and R G2 , or R G5 and R G6 combine to form an optionally substituted cycloalkyl or heterocyclyl; and
• R G1 is unsubstituted phenyl and R G2 is H, R G5 and R G6 do not combine to form unsubstituted cyclopentyl;
• R G1 or R G5 is phenyl having 0, 1, 2, 3, 4, or 5 substituents. In certain embodiments, R G1 is unsubstituted phenyl.
• R G2 or R G6 is phenyl having 0, 1, 2, 3, 4, or 5 substituents.
• R G1 and R G2 , or R G5 and R G6 combine to form an optionally substituted cycloalkyl.
• the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
• the invention features a pharmaceutical composition including a pharmaceutically acceptable excipient and any compound of Formulas (I)-(VIII), or any of Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70), or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof.
• the invention features a method of treating a condition in a subject, with the method including the step of administering the compound of any compound of Formulas (I)-(VIII), or any of Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70), or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof, to said subject in a dosage sufficient to decrease necroptosis.
• the condition is a neurodegenerative disease of the central or peripheral nervous system, the result of retinal neuronal cell death, the result of cell death of cardiac muscle, the result of cell death of cells of the immune system; stroke, liver disease, pancreatic disease, the result of cell death associated with renal failure; heart, mesenteric, retinal, hepatic or brain ischemic injury, ischemic injury during organ storage, head trauma, septic shock, coronary heart disease, cardiomyopathy, myocardial infarction, bone avascular necrosis, sickle cell disease, muscle wasting, gastrointestinal disease, tuberculosis, diabetes, alteration of blood vessels, muscular dystrophy, graft-versus-host disease, viral infection, Crohn's disease, ulcerative colitis, asthma, or any condition in which alteration in cell proliferation, differentiation or intracellular signaling is a causative factor.
• the condition is a neurodegenerative disease of the central or peripheral nervous system.
• the condition is hepatic or brain ischemic injury, or ischemic injury during organ storage, head trauma, septic shock, or coronary heart disease.
• the condition is stroke.
• the condition is myocardial infarction.
• the invention features a method of decreasing necroptosis, where the method includes contacting a cell with any compound of Formulas (I)-(VIII), or any of Compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), and (58)-(70)), or any pharmaceutically acceptable salt or solvate thereof, or stereoisomer thereof.
• the invention features a kit including
• the compound can be selected from the group consisting of:
• C 1-4 alkaryl is meant a C 1-4 alkyl group having an optionally substituted aryl or an optionally substituted heteroaryl located at any position of the carbon chain.
• the C 1-4 alkyl group may be linear or branched and may also be substituted with, for example, 1, 2, 3, 4, or 5 additional substituents as described herein.
• alkoxy is meant a group having the structure —O(optionally substituted C 1-6 alkyl), where the optionally substituted C 1-6 alkyl may be branched, linear, or cyclic.
• the C 1-6 alkyl may be substituted or unsubstituted.
• a substituted C 1-6 alkyl can have, for example, 1, 2, 3, 4, 5, or 6 substituents located at any position.
• Exemplary alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, and the like.
• C 2-6 alkenyl or “alkenyl” is meant an optionally substituted unsaturated C 2-6 hydrocarbon group having one or more carbon-carbon double bonds.
• exemplary C 2-6 alkenyl groups include, but are not limited to —CH ⁇ CH (ethenyl), propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like.
• a C 2-6 alkenyl may be linear or branched and may be unsubstituted or substituted.
• a substituted C 2-6 alkenyl may have, for example, 1, 2, 3, 4, 5, or 6 substituents located at any position.
• C 1-6 alkyl or “alkyl” is meant an optionally substituted C 1-6 saturated hydrocarbon group.
• An alkyl group may be linear, branched, or cyclic (“cycloalkyl”).
• alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, sec-pentyl, iso-pentyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, sec-hexyl, n-heptyl, n-octyl, n-decyl, n-undecyl, dodecyl, and the like, which may bear one or more sustitutents.
• Substituted alkyl groups may have, for example, 1, 2, 3, 4, 5, or 6 substitutents located at any position.
• C 2-6 alkynyl or “alkynyl” is meant an optionally substituted unsaturated C 2-6 hydrocarbon group having one or more carbon-carbon triple bonds.
• exemplary C 2-6 alkynyl groups include, but are not limited to ethynyl, 1-propynyl, and the like
• amino is meant a group having a structure —NR′R′′, where each R′ and R′′ is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or R′ and R′′ combine to form an optionally substituted heterocyclyl.
• R′ and R′′ may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
• aryl is meant is an optionally substituted C 6 -C 14 cyclic group with [4n+2] ⁇ electrons in conjugation and where n is 1, 2, or 3.
• aryls include heteroaryls and, for example, benzene, naphthalene, anthracene, and phenanthrene.
• Aryls also include bi- and tri-cyclic ring systems in which a non-aromatic saturated or partially unsaturated carbocyclic ring (e.g., a cycloalkyl or cycloalkenyl) is fused to an aromatic ring such as benzene or napthalene.
• Exemplary aryls fused to a non-aromatic ring include indanyl, tetrahydronaphthyl. Any aryls as defined herein may be unsubstituted or substituted. A substituted aryl may be optionally substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents located at any position of the ring.
• aryloxy is meant a group having the structure —O(optionally substituted aryl), where aryl is as defined herein.
• azido is meant a group having the structure —N 3 .
• carbamate or “carbamoyl” is meant a group having the structure —OCONR′R′′ or —NR′CO 2 R′′, where each R′ and R′′ is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or R′ and R′′ combine to form an optionally substituted heterocyclyl.
• R′ and R′′ may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
• carbonate is meant a group having a the structure —OCO 2 R′, where R′ is selected from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• R′ is selected from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• R′ is not H, R may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
• Carboxamido or “amido” is meant a group having the structure —CONR′R′′ or —NR′C( ⁇ O)R′′, where each R′ and R′′ is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or R′ and R′′ combine to form an optionally substituted heterocyclyl.
• R′ and R′′ may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
• carboxylic group is meant a group having the structure —CO 2 R′, where R′ is selected from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• R′ is selected from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• R′ is not H, R may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
• cyano is meant a group having the structure —CN.
• C 3-10 cycloalkyl or “cycloalkyl” is meant an optionally substituted, saturated or partially unsaturated 3- to 10-membered monocyclic or polycyclic (e.g., bicyclic, or tricyclic) hydrocarbon ring system.
• a cycloalkyl is polycyclic, the constituent cycloalkyl rings may be fused together, form a spirocyclic structure, or the polycyclic cycloalkyl may be a bridged cycloalkyl (e.g., adamantyl or norbonanyl).
• cycloalkyls includece cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Cycloalkyls may be unsubstituted or substituted. A substituted cycloalkyl can have, for example, 1, 2, 3, 4, 5, or 6 substituents.
• cycloalkenyl is meant a non-aromatic, optionally substituted 3- to 10-membered monocyclic or bicyclic hydrocarbon ring system having at least one carbon-carbon double bound.
• a cycloalkenyl may have 1 or 2 carbon-carbon double bonds.
• Cycloalkenyls may be unsubstituted or substituted.
• a substituted cycloalkenyl can have, for example, 1, 2, 3, 4, 5, or 6 substituents.
• Exemplary cycloalkenyls include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, and the like.
• an effective amount or “therapeutically effective amount” of an agent is that amount sufficient to effect beneficial or desired results, such as clinical results, and, as such, an effective amount depends upon the context in which it is being applied.
• an effective amount of an agent is, for example, an amount sufficient to achieve a reduction in necroptosis as compared to the response obtained without administration of the agent.
• esters is meant a group having a structure selected from —OCOR′, where R′ is selected from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• R′ is not H, R may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
• halogen or “halo” is meant fluorine (—F), chlorine (—Cl), bromine (—Br), or iodine (—I).
• heteroaryl is mean an aryl group that contains 1, 2, or 3 heteroatoms in the cyclic framework.
• exemplary heteroaryls include, but are not limited to, furan, thiophene, pyrrole, thiadiazole (e.g., 1,2,3-thiadiazole or 1,2,4-thiadiazole), oxadiazole (e.g., 1,2,3-oxadiazole or 1,2,5-oxadiazole), oxazole, benzoxazole, isoxazole, isothiazole, pyrazole, thiazole, benzthiazole, triazole (e.g., 1,2,4-triazole or 1,2,3-triazole), benzotriazole, pyridines, pyrimidines, pyrazines, quinoline, isoquinoline, purine, pyrazine, pteridine, triazine (e.g, 1,2,3-triazine, 1,2,4-tria
• heterocyclic or “heterocyclyl” is meant an optionally substituted non-aromatic, partially unsaturated or fully saturated, 3- to 10-membered ring system, which includes single rings of 3 to 8 atoms in size, and polycyclic ring systems (e.g., bi- and tri-cyclic ring systems) which may include an aryl (e.g., phenyl or naphthyl) or heteroaryl group that is fused to a non-aromatic ring (e.g., cycloalkyl, cycloalkenyl, or heterocyclyl), where the ring system contains at least one heterotom.
• polycyclic ring systems e.g., bi- and tri-cyclic ring systems
• aryl e.g., phenyl or naphthyl
• heteroaryl group e.g., cycloalkyl, cycloalkenyl, or heterocyclyl
• Heterocyclic rings include those having from one to three heteroatoms independently selected from oxygen, sulfur, and nitrogen, in which the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized or substituted.
• the term heterocylic refers to a non-aromatic 5-, 6-, or 7-membered monocyclic ring wherein at least one ring atom is a heteroatom selected from O, S, and N (wherein the nitrogen and sulfur heteroatoms may be optionally oxidized), and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms.
• heterocycle is polycyclic
• the constituent rings may be fused together, form a spirocyclic structure, or the polycyclic heterocycle may be a bridged heterocycle (e.g., quinuclidyl or.
• exemplary heterocyclics include, but are not limited to, aziridinyl, azetindinyl, 1,3-diazatidinyl, pyrrolidinyl, piperidinyl, piperazinyl, thiranyl, thietanyl, tetrahydrothiophenyl, dithiolanyl, tetrahydrothiopyranyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, pyranonyl, 3,4-dihydro-2H-pyranyl, chromenyl, 2H-chromen-2-onyl, chromanyl, dioxanyl (e.g., 1,
• ketone or “acyl” is meant a group having the structure —COR′, where R′ is selected from H, optionally substituted C 1-6 alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• R′ is not H, R may be unsubstituted or substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents.
• nitro is meant a group having the structure —NO 2 .
• a “pharmaceutically acceptable excipient” as used herein refers any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being nontoxic and non-inflammatory in a patient.
• Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspensing or dispersing agents, sweeteners, or waters of hydration.
• excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, B
• pharmaceutically acceptable salt represents those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio.
• Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66:1-19.
• the salts can be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting the free base group with a suitable organic acid.
• Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphersulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pe
• alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine and the like.
• solvates refers to compounds that retain non-covalent associations to residual solvent molecules in the solid state.
• solvates may be prepared by crystallization, recrystallization, or precipitation from a solution that includes organic solvents, water, or a mixture thereof.
• Solvates include, but are not limited to, compounds that include solvent molecules in the crystal lattice following recrystallization.
• the molecular stoichiometry of solvation can vary from, for example, 1:1 solvent:compound to 10:1 solvent:compound. These ratios can include a mixture of associated solvent molecules.
• NMP N-methylpyrrolidinonc
• DMSO dimethyl sulfoxide
• DMF N,N′-dimethylformamide
• DMAC N,N′-dimethylacetamide
• DMEU 1,3-dimethyl-2-
• composition a composition containing a compound of the invention, formulated with a pharmaceutically acceptable excipient, and manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal. Excipients consisting of DMSO are specifically excluded.
• Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or any other formulation described herein.
• stereoisomer is meant a diastereomer, enantiomer, or epimer of a compound.
• a chiral center in a compound may have the S-configuration or the R-configuration.
• Enantiomers may also be described by the direction in which they rotate polarized light (i.e., (+) or ( ⁇ )).
• Diastereomers of a compound include stereoisomers in which some, but not all, of the chiral centers have the opposite configuration as well as those compounds in which substituents are differently oriented in space (for example, trans versus cis).
• substituents include, but are not limited to: C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, halogen; azido(—N 3 ), nitro (—NO 2 ), cyano (—CN), acyloxy(—OC( ⁇ O)R′), acyl (—C( ⁇ O)R′), alkoxy (—OR′), amido (—NR′C( ⁇ O)R′′ or —C( ⁇ O)NRR′), amino (—NRR′), carboxylic acid (—CO 2 H), carboxylic ester (—CO 2 R′), carbamoyl (—OC( ⁇ O)NR′R′′ or —NRC( ⁇ O)OR′), hydroxy (—OH), isocyano (—NC), sulfon
• a substituted group may have, for example, 1, 2, 3, 4, 5, 6, 7, 8, or 9 substituents.
• each hydrogen in a group may be replaced by a substituent group (e.g., perhaloalkyl groups such as CF 3 or —CF 2 CF 3 or perhaloaryls such as —C 6 F 5 ).
• a substitutent group may itself be further substituted by replacing a hydrogen of said substituent group with another substituent group such as those described herein.
• Substituents may be further substituted with, for example, 1, 2, 3, 4, 5, or 6 substituents as defined herein.
• a lower C 1-6 alkyl or an aryl substituent group e.g., heteroaryl, phenyl, or naphthyl
• heterocyclic compounds of the invention include, for example, compounds of Formulas (I)-(VIII), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, and are shown to inhibit TNF- ⁇ induced necroptosis in FADD-deficient variant of human Jurkat T cells. Still other useful necrostatins include Compounds (1)-(45).
• Compounds of the invention can be synthesized according to methods known in the art or by the methods provided in the examples below. Pharmaceutical compositions including the compounds of the invention are also described. The invention also features kits and methods of treatment featuring the compounds and compositions of the invention.
• each X H1 and X H2 is selected, independently, from O, S, or NR H9 ;
• Y H1 is selected, independently, from O, S, or NR H10 ;
• each R H1 , R H2 , R H3 , R H4 , R H5 , R H6 , R H7 , and R H8 is selected, independently from H, halogen, cyano, nitro, azido, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —C( ⁇ O)R H12 , —C( ⁇ O)OR H12 , —C( ⁇ O)NR H12 R H13 , —C( ⁇ S)R H12 , —C( ⁇ S)NR H12 R H13 , —C( ⁇ NR H14 )R H12 , —C( ⁇ NR H14 )NR H12 R H13 , or —[Z H1 —(CR H15 R H16
• each Z H1 and Z H2 is selected, independently, from a single bond, O, S, or NR H11 ;
• each R H9 , R H10 , R H11 , R H12 , R H13 , R H14 , R H15 , R H16 , and R H17 is selected, independently from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;
• n is an integer between 0-6;
• o 0 or 1
• each R H1 and R H3 is selected, independently, from H, halogen, cyano, nitro, azido, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, —C( ⁇ O)R H12 , —C( ⁇ O)OR H12 , or —C( ⁇ O)NR H12 R H13 , or R H1 and R H3 combine to form a carbon-carbon double bond;
• each R H4 and R H17 is selected, independently, from optionally substituted aryl or optionally substituted heteroaryl;
• R H5 is selected from H, CN, —C( ⁇ O)OR H12 , or —C( ⁇ O)NR H12 R H13 ;
• each R H10 , R H11 , R H12 , and R H13 is selected from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;
• Z H1 is selected from a single bond or S
• Z H2 is selected from a single bond or NR H11 ;
• X H2 is O or S
• the compound has a structure according to the following formula:
• R H4 is as according to Formula (I-A) or (I-B).
• R H1 is H
• R H2 is H or CO 2 Me
• R H3 is H
• R H4 is unsubstituted phenyl or phenyl substituted with 1, 2, or 3 substituents selected from methoxy, ethoxy, methyl, isopropyl, chloro, or fluoro
• R H5 is CN
• R H6 and R H8 is H
• R H10 is H
• X H1 is O
• Y H1 is NH
• R H7 is —[S—(CH 2 )— ⁇ C( ⁇ O) ⁇ o —Z H2 —R 17 ]
• Z H2 —R F17 is not OCH 3 or NH—R H17 , where R H17 is H, unsubstituted 2-thiazolyl, unsubstituted phenyl, 4-methoxyphenyl, 4-fluorophenyl, or 2,4,6-trimethylphenyl.
• Compounds of Formula (I) can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits).
• Exemplary compounds useful in the methods, compositions, and kits of the invention include but are not limited to those shown in Table 1.
• Other compounds of Formula I are shown in Table 2.
• Formulas (I), (I-A), (I-B), or (I-C) do not include any of Compounds (1)-(12).
• each R A1 , R A2 , R A3 , R A4 , R A5 , and R A6 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a group having the structure —X A1 -G A1 -X A2 —C( ⁇ Y A1 )-G A2 -X A3 —R A7 , or R A1 and R A4 combine to form a carbon-carbon double bond;
• each X A1 , X A2 , and X A3 is, independently, absent or selected from —O—, —S—, or —NR A8 —;
• G A1 is absent or —(CR A9 R A10 ) m —;
• G A2 is absent or —(CR A11 R A12 ) n —;
• Y A1 is O, S, or NR A13 ;
• each R A8 and R A13 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —COR A14 , —CO 2 R A14 , or —CONR A14 R A15 ;
• each R A9 , R A10 , R A11 , and R A12 is selected, independently, from H, halogen, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each R A7 , R A14 and R A15 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl; and
• each m and n is, independently, 1, 2, or 3;
• R A1 and R A4 when R A1 and R A4 combine to form a carbon-carbon double bond, R A2 is H, R A3 is CH 3 , and R A6 is CO 2 H, R A5 is not CH 2 (2-chlorophenyl).
• R A1 and R A4 when R A1 and R A4 combine to form a carbon-carbon double bond, R A2 is H, R A6 is CH 3 or t Bu, and R A3 is NHC( ⁇ O)NHR A7 , R A7 is not chlorophenyl or dichlorophenyl.
• each R A1 , R A3 , R A4 , and R A7 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R A1 and R A4 combine to form a carbon-carbon double bond;
• G A2 is absent or is —(CR A11 R A12 ) n —;
• X A3 is absent or is O, S, or NR A8 ;
• each R A11 , R A12 , and R A8 is selected, independently, from H or optionally substituted C 1-6 alkyl;
• n 1 or 2;
• R A5 is H
• each R A1 , R A2 , R A3 , R A4 , and R A6 is selected, independently, from H, optionally substituted aryl, optionally substituted heteroaryl, —C( ⁇ O)—X A3 —R A7 , or R A1 and R A4 combine to form a carbon-carbon double bond;
• each R A7 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
• each X A3 is, independently, absent, —O—, or —NR A8 —,
• R A1 and R A4 when one of R A1 and R A4 is H and the other is selected from H or CO 2 Et, and R A3 is unsubstituted phenyl, G A2 -X A3 —R A7 is not NHC 6 H 5 , NH(p-C 6 H 4 F), NH(p-C 6 H 4 OH), NH(p-C 6 H 4 OMe), NH(3-OH-4-Cl—C 6 H 4 ), —CH 2 (O-p-C 6 H 4 Me), —CH 2 (4-ethylpiperazinyl), —CH 2 S(2-phenyltetrazolyl), —CH 2 S(4-chlorophenyl), —CH 2 S(2-benzothiazolyl), —CH 2 S(2-(N-methylimidazolyl)), —CH 2 S(4,6-dimethylquina
• each R A1 , R A2 , R A4 , and R A6 is selected, independently, from H, —C( ⁇ O)—X A3 —R A7 , optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R A1 and R A4 combine to form a carbon-carbon double bond;
• each X A3 is, independently, absent, —O—, or —NR A8 —,
• each R A8 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —COR A14 , —CO 2 R A14 , or —CONR A14 R A15 ; and
• each R A7 , R A14 and R A15 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl.
• R A6 is not 4-chlorophenyl, 4-methoxyphenyl, or 4-(NHCO 2 t Bu)phenyl.
• R A1 is H
• R A4 is H or CO 2 Et
• R A2 is unsubstituted phenyl
• R A6 is not —C( ⁇ O)-(unsubstituted phenyl) or —C( ⁇ O)-(4-methylphenyl).
• R A1 is H
• R A4 is —C( ⁇ O)-(unsubstituted phenyl
• R A2 is 4-chlorophenyl
• R A6 is not CO 2 Et.
• Scheme 2A shows a method that can be used to prepare pyrazole compounds of Formula (II). Terminal alkynes can be reacted with trimethylsilyldiazomethane (TMS-diazomethane) to afford compounds of Formula (II) where R A1 and R A4 combine to form a carbon-carbon double bond and R′ can be, for example, optionally substituted aryl or optionally substituted heteroaryl.
• Scheme 2B shows the preparation of Compound (13) using the method in Scheme 2A in which the aniline —NH 2 group is protected prior to the reaction with TMS-diazomethane.
• Scheme 3A depicts another method that can be used to synthesize pyrazoline compounds of Formula (II) according to methods described in J. Chem. Soc. 4686-90 (1952) and J. Med. Chem. 2127-2137 (2006).
• substituted acroleins e.g., R′ can be optionally substituted aryl or optionally substituted heteroaryl
• Step (a) ethanolic hydrazine
• the pyrazoline can then be treated with an electrophilic compound having a suitable leaving group (e.g., alkyl halides, acid cholorides. or acid anhydrides) and an optional chemical promotoer to afford N-substituted pyrazolines.
• Scheme 3B shows a method that can be used to prepare Compound (14) where an acid chloride can be used in Step (b) as shown.
• Scheme 4 shows Compound (15) which can be prepared according to the procedure described in J. Am. Chem. Soc., page 165 (1943). This method can also be used to prepare other pyrazoline compounds of Formula (II), where R A6 is —C( ⁇ O)—R A7 and R A2 and R A7 are, independently, optionally substituted aryl or optionally substituted heteroaryl.
• Scheme 5A depicts a method by which tetrazole compounds of Formula (II) can be prepared using methods described in WO2005115147 and in J. Med. Chem., 4686-90 (1952).
• a tetrazole compound that includes a carboxylic acid group can be activated (e.g., treatment with PCl 5 as in Step (a)) and subsequently treated with a nucleophile R′′ as in Step (b).
• Scheme 5B shows that 5-Phenyl-4,5-dihydro-1H-pyrazole can be used as the nucleophile in step (b′) to afford Compound (16).
• Compounds of Formula (II) can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits). Additional exemplary compounds useful in, for example, the methods, compositions, and kits of the invention, include but are not limited to those shown in Table 3. Other compounds of Formula (II) are shown in Table 4. In some embodiments, Formula (II), (II-A), and (II-B) do not include any of compounds (13)-(26).
• R B1 is selected from H, optionally substituted C 1-6 alkyl, —C( ⁇ O)R B18 , —C( ⁇ O)OR B18 , or —C( ⁇ O)NR B18 R B19 ;
• R B2 is selected from H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, or optionally substituted C 2-6 alkynyl;
• each R B3 and R B4 is selected, independently from H, optionally substituted C 1-6 alkyl, or R B3 and R B4 combine to form a bridging group having the structure —(CH 2 ) n —(CR B13 ⁇ CR B14 ) o —(CH 2 ) p —;
• each n, o, and p is, independently, 0 or 1;
• each R B5 , R B6 , R B7 , R B8 , R B9 , R B10 , R B11 , and R B12 is selected, independently, from H, halogen, —CN, —NO 2 , —N 3 , —R B13 , —OR B13 , —SR B13 , —NR B13 R B14 , —C( ⁇ O)R B15 , —C( ⁇ O)OR B15 , —C( ⁇ O)NR B15 R B16 , —OC( ⁇ O)R B15 , —OC( ⁇ O)OR B15 , —OC( ⁇ O)NR B15 R B16 , —NR B15 C( ⁇ O)R B15 , —NR B15 C( ⁇ O)OR B16 , —NR B15 C( ⁇ O)NR B16 R B17 , —C( ⁇ S)R B15 , —C( ⁇ S)NR B15 R B16 , —
• each R B13 and R B14 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, —C( ⁇ O)OR B18 , or —C( ⁇ O)NR B18 R B19 ;
• each R B15 , R B16 , R B17 , R B18 , and R B19 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; and
• R B1 is as described in Formula (III)
• R B2 is ethyl, ethenyl, or ethynyl and each R B9 , R B10 , R B11 , and R B12 is selected, independently, from H and halogen,
• R B1 is H.
• R BI is as described in Formula (III)
• R B2 is ethyl, ethenyl, or ethynyl and each R B9 , R B10 , R B11 , and R B12 is selected, independently, from H and halogen,
• R B1 is H.
• R B1 is not H or CH 3 when R B5 , R B6 , R B7 , R B8 , R B9 , R B10 , R B11 , and R B12 are each H, R B2 is ethyl, ethenyl, ethynyl, propynyl, 2-haloethynyl, —(C ⁇ CC(—OH)(CH 3 ) 2 ), and when R B3 and R B4 are each H or combine to form a bond, —CH 2 CH 2 — or —CH ⁇ CH—.
• R B1 is not H when R B5 , R B6 , R B7 , R B8 , R B10 , and R B11 are each H, at least one of R B9 or R B12 is fluoro, R B2 is ethynyl, and when R B3 and R B4 combine to form —CH 2 CH 2 —.
• R B1 is not H when R B6 , R B7 , R B8 , R B10 , and R B11 are H and one or two of R B6 , R B8 , R B10 , and R B12 is halogen, nitro, or methyl.
• Scheme 6A depicts a method by which compounds of Formula (III) can be prepared.
• a ketone derivative can be treated with an anionic carbon nucleophile (e.g., lithium trimethylsilylacetylide formed in step (a)).
• the resulting alkoxide can be trapped using a protic quench or by the addition of an electrophilic reagent.
• the trimethylsilyl group can be deprotected using basic conditions.
• the alkyne group can be further manipulated (e.g., subjected to hydrogenation conditions to afford the corresponding alkene or alkyl group or treated with a metal catalyst/and organic electrophile in cross-coupling reactions).
• Scheme 6B shows Compound (27), which can be prepared using these conditions.
• Compounds of Formula (III) (e.g., (III-A) and (III-B) and compound (27)), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits). Additional exemplary compounds useful in, for example, the methods, compositions, and kits of the invention, include but are not limited to those shown in Table 5.
• Other compounds of Formula (III) include Compounds (35)-(36), (39)-(40), and (42)-(47) shown in Table 6. In some embodiments, Formula (III) does not include any of Compounds (27)-(33), (35)-(36), (39)-(40), or (42)-(47).
• each R C1 , R C2 , and R o is selected, independently, from H, optionally substituted C 1-6 alkyl, —Y—R C7 , or R C1 and R C2 combine to form a ( ⁇ O) or a ( ⁇ S) group, or R C1 and R C3 combine to form a carbon-nitrogen double bond;
• R C4 is selected from H, halogen, —CN, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or —C( ⁇ O)ZR C8 ,
• each R C5 and R C6 is selected, independently, from H, optionally substituted C 1-6 alkyl, or R C1 and R C2 combine to form an optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each R C7 , R C8 , R C9 , R C10 , R C11 , and R C12 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• X is —CR C11 —CR C12 —, O, S, or NR C9 ;
• Y is, independently, a single bond, (CR C8 R C9 ) n , O, S, or NR C10 ;
• Z is a single bond, O, S, or NR C10 ;
• R C1 and R C2 combine to form a ( ⁇ O) group
• R C4 is H
• R C5 and R C6 combine to form unsubstituted cyclopentyl
• R C3 is not —CH 2 —R C7 , where R C7 is unsubstituted phenyl, unsubstituted naphthyl, unsubstituted 8-quinolyl, unsubstituted 2-oxoquinolyl, or phenyl having 1 or 2 substituents selected from F, OMe, Me, CN, or Cl.
• R C1 and R C2 when X is S, R C1 and R C2 combine to form a ( ⁇ O) group, R C4 is H, and R C5 and R C6 are each Me, R C3 is not —CH 2 —R C7 , where R C7 is unsubstituted phenyl.
• R C3 when X is CH ⁇ CH, R C1 and R C2 combine to form a ( ⁇ O) group, R C4 , R C5 and R C6 are H, R C3 is not —CH 2 (4-halophenyl).
• X, R C1 , R C2 , R C3 , and R C4 are as defined for Formula (IV) and n is an integer between 0-3,
• Scheme 7A depicts a method by which compounds of Formula (IV) (e.g., compounds of Formula (IV-A)) can be prepared.
• a heterocyclic derivative can be deprotonated using a base such as NaH and subsequently treated with an electrophile (e.g., an alkyl halide such as benzyl bromide, an acid chloride, or an acid anhydride) to afford a compound of Formula (IV) such as Compound (48) shown in Scheme 7B.
• an electrophile e.g., an alkyl halide such as benzyl bromide, an acid chloride, or an acid anhydride
• Compounds of Formula (IV) can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits). Additional exemplary compounds useful in, for example, the methods, compositions, and kits of the invention, include but are not limited to those shown in Table 7. In some embodiments, Formula (IV) does not include any of Compounds (48)-(57).
• each X D1 and X D2 is selected, independently, from O, S, NR D5 , or CR D6 R D7 ;
• Y D1 is selected from a covalent bond, —C( ⁇ O)—, —S( ⁇ O)—, or —S( ⁇ O) 2 —;
• Y D2 is selected from a covalent bond, —C( ⁇ O)—, —OC( ⁇ O)—, —NR D8 C( ⁇ O)—, —S( ⁇ O)—, —S( ⁇ O) 2 —, —OS( ⁇ O)—, —OS( ⁇ O) 2 —, —NR D8 S( ⁇ O)—, —NR D8 S( ⁇ O) 2 —, or —C( ⁇ S)—;
• A is selected from optionally substituted aryl or optionally substituted heteroaryl
• G D1 is selected from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, OR D9 , or NR D9 R D10 ;
• each R D1 , R D2 , R D3 , R D4 , R D6 , R D7 is selected, independently, from H, halogen, CN, NC, N 3 , NO 2 , OR D11 , SR D11 , NR D11 R D12 , —COR D13 , —CO 2 R D13 , —CONR D13 R D14 , optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R D1 and R D4 , or R D1 and R D5 , or R D1 and R D6 , or R D3 and R D5 , or R D3 and R D6 combine to form a double bond;
• each R D5 , R D8 , R D9 , R D10 , R D13 , R D14 , R D15 , and R D16 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R D9 and R D10 combine to form a heterocyclyl;
• each R D11 and R D12 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —COR D15 , —CO 2 R D15 , —CONR D15 R D16 , —S( ⁇ O)R D15 , —S( ⁇ O)OR D15 , —S( ⁇ O)NR D15 R D16 , —S( ⁇ O) 2 R D15 , —S( ⁇ O) 2 OR D15 , —S( ⁇ O) 2 NR D15 R D16 ;
• each Y D1 and Y D2 is selected, independently, from —C( ⁇ O)— or —S( ⁇ O) 2 —;
• A is phenyl having 0, 1, 2, 3, or 4 additional substituents
• R D2 and R D3 are selected, independently from H, halogen, CN, NC, N 3 , NO 2 , —COR D13 , —CO 2 R D13 , —CONR D13 R D14 , optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each R D5 ; R D9 , R D10 , R D13 , and R D14 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R D9 and R D10 combine to form a heterocyclyl; or by Formula (V-B)
• each R D2 , R D3 , R D17 , R D18 , R D19 , and R D20 is selected, independently from H, halogen, CN, NC, N 3 , NO 2 , —COR D13 , —CO 2 R D13 , —CONR D13 R D14 , optionally substituted C 1-6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; and
• each R D9 and R D10 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, or optionally substituted aryl, or R D9 and R D10 combine to form a heterocyclyl;
• R D1 and R D4 when R D1 and R D4 combine to form a double bond, R D2 and R D3 are H, X D1 is NH, X D2 is S, Y D1 is —(C ⁇ O)—, Y D2 is —(SO 2 )—, G D1 is —N(Et) 2 , and A is phenyl having no additional substituents, Y D1 and Y D2 are not para to each other.
• Compounds of Formula (V) can be prepared, for example, by treating an aryl or heteroaryl compound that has two electrophilic groups successively with nucleophilic reagents to afford the desired compound.
• nucleophilic reagents for example, as shown in Scheme 8 and using procedures adapted from Heterocyclic Communications, 12(6): 453-456 (2006) and Organic Synthesis, Collective Vol. 6, page 818, the difunctional benzene derivative 4-CO 2 Hphenylsulfonyl chloride can be treated with a nucleophile such as diethylamine to afford the corresponding sulfonamide.
• step (c) can then be condensed with a carbonyl-containing compound to afford compounds of Formula (V) such as Compound (58).
• Compounds of Formula (V) (e.g., (V-A) and (V-B) and compound (34)), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits).
• Formulas (V), (V-A), and (V-B) do not include Compounds (58).
• each X E1 and X E3 is selected, independently, from N or CR E4 ;
• each X E4 and X E5 is selected, independently, from O, S, or NR E5 ;
• X E2 is selected from O, S, or N;
• each Z E1 , Z E2 , and Z E3 is selected, independently, from a single bond, —(CR E6 R E7 ) n —, —C(O)—, —S( ⁇ O)—, or —S( ⁇ O) 2 —, or Z E1 —R E2 and Z E2 —R E2 combine to form a double bond;
• each R E1 , R E2 , R E3 , R E4 , R E5 , R E6 , and R E7 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• p is 0 or 1
• n is an integer between 1-6;
• each R E1 , R E2 , R E3 , R E4 , R E5 , R E6 , and R E7 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl
• R E3 is selected from substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• X E1 when p is 0, X E1 is CH, —Z E1 —R E1 is —CH 2 (indol-3-yl), X E4 and X E5 are O, and X E2 —Z E2 —R E2 is NH, X E3 —Z E3 —R E3 is not —NCH 2 (p-ClC 6 H 4 ) or —NCH 2 CH 2 O(p-FC 6 H 4 ).
• X E1 —Z E1 —R E1 is NH
• X E2 —Z E2 is CH—CH 2
• R E2 is unsubstituted or substituted 3-indolyl
• p is 0 or 1
• both X E4 and X E5 are O or X E4 is S and X E5 is O
• X E3 is N
• Z E3 is CH 2
• R E3 is not H, unsubstituted C 1-6 alkyl, or —CH 2 CH ⁇ CH 2 .
• the R E3 group can be unsubstituted.
• a substituted R E3 group includes 1, 2, 3, 4, or 5 substituents selected from, for example, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, azido(—N 3 ), alkoxy (—OR′), amido (—NR′C( ⁇ O)R′′ or —C( ⁇ O)NRR′), amino (—NRR′), carbamoyl (—OC( ⁇ O)NR′R′′ or —NRC( ⁇ O)OR′), hydroxy (—OH), or isocyano (—NC), where each R or R′ is selected, independently, from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
• the substituted R E3 group includes 1, 2, 3, or 4 substituents that are
• Certain compounds of Formula (VI) may be described by Formula (VI-A) or Formula (VI-B)
• each Z E2 and Z E3 is selected, independently, from a single bond, —(CR E6 R E7 ) n —, —C( ⁇ O)—, or R E1 and Z E2 —R E2 combine to form a double bond;
• each R E1 , R E2 , R E3 , and R E4 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each R E6 and R E7 is selected, independently, from H or optionally substituted C 1-6 alkyl
• n is an integer between 1-6;
• each R E1 , R E2 , R E3 , and R E4 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• R E3 is selected from substituted C 1-6 alkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
• R E1 and R E4 are H, Z E2 and Z E3 are each CH 2 , and R E2 is unsubstituted 3-indolyl, R E3 is not 4-chlorophenyl.
• each X E4 and X E5 is, independently, O or S;
• X E2 is O or N
• each Z E2 and Z E3 is selected, independently, from a single bond or —(CR E6 R E7 ) n —;
• each R E2 and R E3 is, independently, H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl;
• each R 3 and R 4 is, independently, H, halogen, or optionally substituted C 1-6 alkyl;
• each R 5 , R 6 , R 7 , R 8 , and R 9 is selected, independently, from H, halogen, CN, NO 2 , OR 13 , NR 13 R 14 , COR 15 , CO 2 R 15 , optionally substituted C 1-6 alkyl, or optionally substituted aryl;
• R 10 is selected from H, halogen, CN, NO 2 , OR 13 , NR 13 R 14 , COR 15 , CO 2 R 15 , optionally substituted C 1-6 alkyl, optionally substituted aryl, optionally substituted alkenyl, or optionally substituted alkynyl;
• each R 13 and R 14 is selected, independently, from H, COR 16 , CO 2 R 16 , optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
• each R 11 , R 12 , R 15 , and R 16 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
• n 0, 1, 2, 3, 4, or 5, and p is 0 or 1;
• p is 0.
• R E3 is selected from substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted C 2-6 alkenyl, optionally substituted C 2-6 alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl.
• X E5 is O or S
• each R 3 , R 4 , and R 10 is, independently, H or optionally substituted C 1-6 alkyl;
• R 9 is H, halogen, CN, NO 2 , OR 13 , NR 13 R 14 , COR 15 , CO 2 R 15 , or optionally substituted C 1-6 alkyl;
• each R 13 and R 14 is selected, independently, from H, COR 16 , CO 2 R 16 , optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
• each R 11 , R 12 , R 15 , and R 16 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
• n 1 or 2;
• the compound has a structure according to the following formula:
• the sp 3 -hybridized carbon to which G is attached can have the (R)- or the (S)-configuration.
• compounds of the invention include
• R 10 is H or CH 3 .
• R 9 is H, halogen, optionally substituted C 1-6 alkyl, OH, or —O-(optionally substituted C 1-6 alkyl).
• —Z E3 —R E3 is optionally substituted benzyl. In one embodiment, —Z E3 —R E3 is unsubstituted benzyl. In another embodiment, —Z E3 —R E3 is benzyl having 1, 2, 3, 4, or 5 substituents.
• the substituents are selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, azido(—N 3 ), alkoxy (—OR′), amido (—NR′C( ⁇ O)R′′ or —C( ⁇ O)NRR′), amino (—NRR′), carbamoyl (—OC( ⁇ O)NR′R′′ or —NRC( ⁇ O)OR′), hydroxy (—OH), and isocyano (—NC), as described herein.
• —Z E3 —R E3 is CH 2 — (p-XC 6 H 4 ), where X is halogen.
• X is F or Cl.
• —Z E3 and R E3 do not include substituents selected from the group consisting of: halogen (e.g., F, Cl, Br, or I); nitro (—NO 2 ), cyano (—CN), acyloxy(—OC( ⁇ O)R′), acyl (—C( ⁇ O)R′), carboxylic acid (—CO 2 H), carboxylic ester (—CO 2 R′), sulfonate (—S( ⁇ O) 2 OR), sulfonamide (—S( ⁇ O) 2 NRR′ or —NRS( ⁇ O) 2 R′), or sulfonyl (—S( ⁇ O) 2 R), where each R or R′ is selected, independently, from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, as described herein.
• halogen e.g., F, Cl, Br, or I
• Compounds of Formula (VI) can be prepared, for example, by treating hydantoin compound that has, for example, a substituent R at the 5-position with a base followed by trapping with an electrophilic reagent (Scheme 9A).
• Scheme 9B shows that the synthesis of Compound (59) can be achieved by the use of 4-chlorobenzylbromide as the electrophile.
• Formula (VI) (e.g., compounds of Formulas (VI-A), (VI-B), (VI-C), or (VI-D)) does not include any of the compounds or formulas disclosed in U.S. Pat. Nos. 6,756,394 and 7,253,201, in U.S. Patent Publication No. 20050119260, and in pending U.S. application Ser. Nos. 12/077,320 and 12/086,792, each of which is hereby incorporated by reference.
• Compounds of Formula (VI) (e.g., (VI-A)-(VI-D) and compound (59)), or any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof, can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits).
• Formula (VI) does not include compound (59).
• Z F1 is selected from a single bond, —(CR F10 R F11 ) n —, —C( ⁇ O)—, —S( ⁇ O)—, or —S( ⁇ O) 2 —;
• each R F1 , R F2 , R F4 , R F10 , R F11 , R F12 , and R F13 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R F2 and R F4 combine to form a carbon-carbon double bond;
• each R F3 and R F5 is selected, independently, from H, halogen, CN, CO 2 R F12 , optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• each R F6 , R F7 , R F8 , and R F9 is selected, independently, from H, halogen, CN, NC, N 3 , NO 2 , OR F12 , SR F12 , NR F12 R F13 , —COR F12 , —CO 2 F12 , —CONR F12 R F13 , optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
• n is an integer between 1-6;
• Z F1 is selected from a single bond, —(CH 2 )—, —C( ⁇ O)—, or —S( ⁇ O) 2 —;
• R F1 is selected from H, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R F2 and R F4 are each H, or R F2 and R F4 combine to form a carbon-carbon double bond;
• each R F6 , R F7 , R F8 , and R F9 is selected, independently, from H, halogen, CN, NC, N 3 , NO 2 , OR F12 , SR F12 , NR F12 R F13 , —COR F12 , —CO 2 F12 , —CONR F12 R F13 , optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and
• each R F12 and R F13 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
• R F1 is not -(unsubstituted 1,4-benzodioxane) or —CH 2 —(O-(unsubstituted phenyl)).
• Scheme 10 provides a method by which compounds of Formula (VII) such as Compound (60) can be prepared.
• a nucleophilic compound such as indoline can be treated with an electrophile (e.g., a compound containing a carboxylic acid) in the presence of an optional promoter such as DEAD/PPh 3 to afford the requisite compound.
• an electrophile e.g., a compound containing a carboxylic acid
• an optional promoter such as DEAD/PPh 3
• Formulas (VII) e.g., (VII-A) and compound (60)
• any pharmaceutically acceptable salt or solvate thereof, or any stereoisomer thereof can also be used as described herein (e.g., in pharmaceutical compositions, as inhibitors of necroptosis, in methods of treatment, and in kits).
• Formulas (VII) and (VII-A) do not include compounds (60) or (61).
• X G1 is selected from —O—, —N—, or —(CR G9 R G10 ) n —;
• X G2 and X G3 are selected, independently, from N or CR G11 ,
• each R G1 , R G2 , R G3 , R G4 , R G5 , R G6 , R G7 , R G8 , R G9 , R G10 , and R G11 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R G1 and R G2 , or R G3 and R G4 , or R G5 and R G6 , or R G7 and R G8 combine to form an optionally substituted cycloalkyl or heterocyclyl; and
• n 1 or 2;
• each R G1 , R G2 , R G5 , and R G6 is selected, independently, from H, optionally substituted C 1-6 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R G1 and R G2 , or R G5 and R G6 combine to form an optionally substituted cycloalkyl or heterocyclyl,
• R G1 when R G1 is unsubstituted phenyl and R G2 is H, R G5 and R G6 do not combine to form unsubstituted cyclopentyl,
• Formulas (VIII) and (VIII-A) do not include compound (62).
• the necrostatins described herein can be formulated into pharmaceutical compositions for administration to human subjects in a biologically compatible form suitable for administration in vivo.
• the present invention provides a pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable excipient.
• Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2003-20 th edition) and in The United States Pharmacopeia: The National Formulary (USP 24 NF19), published in 1999.
• the compounds may be used in the form of the free base, in the form of salts, solvates, and as prodrugs. All forms are within the scope of the invention.
• the described compounds or salts, solvates, or prodrugs thereof may be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art.
• the compounds of the invention may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump, or transdermal administration and the pharmaceutical compositions formulated accordingly.
• Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal, and topical modes of administration. Parenteral administration may be by continuous infusion over a selected period of time.
• Pharmaceutically acceptable excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspensing or dispersing agents, sweeteners, or waters of hydration.
• excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidonc, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A
• any of the compounds described herein may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet.
• a compound of the invention may be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
• a compound may also be administered parenterally.
• the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that may be easily administered via syringe.
• compositions for nasal administration may conveniently be formulated as aerosols, drops, gels, and powders.
• Aerosol formulations typically include a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomizing device.
• the sealed container may be a unitary dispensing device, such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal after use.
• the dosage form comprises an aerosol dispenser
• a propellant which can be a compressed gas, such as compressed air or an organic propellant, such as fluorochlorohydrocarbon.
• the aerosol dosage forms can also take the form of a pump-atomizer.
• compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, where the active ingredient is formulated with a carrier, such as sugar, acacia, tragacanth, or gelatin and glycerine.
• a carrier such as sugar, acacia, tragacanth, or gelatin and glycerine.
• Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base, such as cocoa butter.
• the compounds of the invention may be administered to an animal alone or in combination with pharmaceutically acceptable carriers, as noted above, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration, and standard pharmaceutical practice.
• the amount of active ingredient e.g., a compound of Formulas (I)-(VIII) or any of compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), or (58)-(70)) in the compositions of the invention can be varied.
• active ingredient e.g., a compound of Formulas (I)-(VIII) or any of compounds (1)-(7), (13)-(26), (27)-(33), (48)-(57), or (58)-(70)
• dosage levels of between 0.1 ⁇ g/kg to 100 mg/kg of body weight are administered daily as a single dose or divided into multiple doses.
• the general dosage range is between 250 ⁇ g/kg to 5.0 mg/kg of body weight per day. Wide variations in the needed dosage are to be expected in view of the differing efficiencies of the various routes of administration. For instance, oral administration generally would be expected to require higher dosage levels than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, which are well known in the art. In general, the precise therapeutically effective dosage will be determined by the attending physician in consideration of the above identified factors.
• the compounds disclosed herein can be used to treat disorders where necroptosis is likely to play a substantial role (e.g., cerebral ischemia, traumatic brain injury, a neurodegenerative disease of the central or peripheral nervous system, the result of retinal neuronal cell death, the result of cell death of cardiac muscle, the result of cell death of cells of the immune system; stroke, liver disease, pancreatic disease, the result of cell death associated with renal failure; heart, mesenteric, retinal, hepatic or brain ischemic injury, ischemic injury during organ storage, head trauma, septic shock, coronary heart disease, cardiomyopathy, myocardial infarction, bone avascular necrosis, sickle cell disease, muscle wasting, gastrointestinal disease, tuberculosis, diabetes, alteration of blood vessels, muscular dystrophy
• Compounds disclosed herein can be evaluated for their pharmacological properties in animal models of disease.
• the compounds identified to decrease necrosis or necroptosis may be structurally modified and subsequently used to decrease necrosis or necroptosis, or to treat a subject with a condition in which necrosis or necroptosis occurs.
• the methods used to generate structural derivatives of the small molecules that decrease necrosis or necroptosis are readily known to those skilled in the fields of organic and medicinal chemistry.
• Treatment may be performed alone or in conjunction with another therapy, for example in combination with apoptosis inhibitors, and may be provided at home, the doctor's office, a clinic, a hospital's outpatient department, or a hospital. Treatment generally begins at a hospital so that the doctor can observe the therapy's effects closely and make any adjustments that are needed. The duration of the therapy depends on the age and condition of the patient, as well as how the patient responds to the treatment. Additionally, a person having a greater risk of developing a condition may receive prophylactic treatment to inhibit or delay symptoms of the disease.
• the compounds and methods of the invention can be used to treat any of the following disorders where necroptosis is likely to play a substantial role: a neurodegenerative disease of the central or peripheral nervous system, the result of retinal neuronal cell death, the result of cell death of cardiac muscle, the result of cell death of cells of the immune system; stroke, liver disease, pancreatic disease, the result of cell death associated with renal failure; heart, mesenteric, retinal, hepatic or brain ischemic injury, ischemic injury during organ storage, head trauma, septic shock, coronary heart disease, cardiomyopathy, myocardial infarction, bone avascular necrosis, sickle cell disease, muscle wasting, gastrointestinal disease, tuberculosis, diabetes, alteration of blood vessels, muscular dystrophy, graft-versus-host disease, viral infection, Crohn's disease, ulcerative colitis, asthma, and any condition in which alteration in cell proliferation, differentiation or intracellular signaling is a causative factor.
• Conditions in which alteration in cell proliferation, differentiation or intracellular signaling is a causative factor include cancer and infection, e.g., by viruses (e.g., acute, latent and persistent), bacteria, fungi, or other microbes.
• viruses e.g., acute, latent and persistent
• bacteria e.g., fungi, or other microbes.
• Exemplary viruses are human immunodeficiency virus (HIV), Epstein-Barr virus (EBV), cytomegalovirus (CMV)5 human herpesviruses (HHV), herpes simplex viruses (HSV), human T-Cell leukemia viruses (HTLV)5 Varicella-Zoster virus (VZV), measles virus, papovaviruses (JC and BK), hepatitis viruses, adenovirus, parvoviruses, and human papillomaviruses.
• Exemplary diseases caused by viral infection include, but are not limited to, chicken pox, Cytomegalovirus infections, genital herpes, Hepatitis B and C, influenza, and shingles.
• Exemplary bacteria include, but are not limited to Campylobacter jejuni, Enterobacter species, Enterococcus faecium, Enterococcus faecalis, Escherichia coli (e.g., E. coli O157:H7), Group A streptococci, Haemophilus influenzae, Helicobacter pylori, listeria, Mycobacterium tuberculosis, Pseudomonas aeruginosa, S. pneumoniae, Salmonella, Shigella, Staphylococcus aureus , and Staphylococcus epidermidis .
• Campylobacter jejuni Enterobacter species
• Enterococcus faecium Enterococcus faecalis
• Escherichia coli e.g., E. coli O157:H7
• Group A streptococci Haemophilus influenzae
• Helicobacter pylori listeria
• Exemplary diseases caused by bacterial infection include, but are not limited to, anthrax, cholera, diphtheria, foodborne illnesses, leprosy, meningitis, peptic ulcer disease, pneumonia, sepsis, tetanus, tuberculosis, typhoid fever, and urinary tract infection.
• neurodegenerative diseases are Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, HIV-associated dementia, cerebral ischemia, amyotropic lateral sclerosis, multiple sclerosis, Lewy body disease, Menke's disease, Wilson's disease, Creutzfeldt-Jakob disease, and Fahr disease.
• Exemplary muscular dystrophies or related diseases are Becker's muscular dystrophy, Duchenne muscular dystrophy, myotonic dystrophy, limb-girdle muscular dystrophy, Landouzy-Dejerine muscular dystrophy, facioscapulohumeral muscular dystrophy (Steinert's disease), myotonia congenita, Thomsen's disease, and Pompe's disease.
• Muscle wasting can be associated with cancer, AIDS, congestive heart failure, and chronic obstructive pulmonary disease, as well as include necrotizing myopathy of intensive care.
• Compounds and methods of the invention can additionally be used to boost the immune system, whether or not the patient being treated has an immunocompromising condition.
• the compounds described herein can be used in a method to strengthen the immune system during immunization, e.g., by functioning as an adjuvant, or by being combined with an adjuvant.
• any of the compounds or pharmaceutical compositions of the invention can be used together with a set of instructions, i.e., to form a kit.
• the kit may include instructions for use of the compounds of the invention in a screening method or as a therapy as described herein.
• necroptosis inhibitory activity was performed using a FADD-deficient variant of human Jurkat T cells or with L929 cells treated with TNF- ⁇ as previously described (Degterev et al., Nat. Chem. Biol. 1:112 (2005) and Jagtap et al., J. Med. Chem. 50: 1886 (2007)). Utilizing these conditions the cells efficiently underwent necroptosis. For EC 50 value determinations, cells were treated with 10 ng/mL of human TNF- ⁇ in the presence of increasing concentration of test compounds for 24 hours followed by ATP-based viability assessment.
• necroptosis activity was performed using a FADD-deficient variant of human Jurkat T cells or L929 cells treated with TNF- ⁇ .
• cells 500,000 cells/mL, 100 ⁇ L per well in a 96-well plate
• 10 ng/mL of human TNF- ⁇ in the presence of increasing concentration of test compounds for 24 hours at 37° C. in a humidified incubator with 5% CO 2 followed by ATP-based viability assessment.
• Stock solutions (30 mM) in DMSO were initially prepared and then diluted with DMSO to give testing solutions, which were added to each test well. The final DMSO concentration was 0.5%. Eleven compound test concentrations (0.030-100 ⁇ M) were used. Each concentration was done in duplicate.
• Cell viability assessments were performed using a commercial luminescent ATP-based assay kit (CellTiter-Glo, Promega, Madison, Wis.) according to the manufacturer's instructions. Briefly, 40 ⁇ L of the cell lysis/ATP detection reagent was added to each well. Plates were incubated on a rocking platform for 10 minutes at room temperature and luminescence was measured using a Wallac Victor 3 plate-reader (Perkin Elmer, Wellesley, Mass.). Cell viability was expressed as a ratio of the signal in the well treated with TNF- ⁇ and compound to the signal in the well treated with compound alone. This was done to account for nonspecific toxicity, which in most cases was ⁇ 10%. EC 50 values were calculated using nonlinear regression analysis of sigmoid dose-response (variable slope) curves from plots of log [I] verses viability values.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Neurology (AREA)
• Diabetes (AREA)
• Biomedical Technology (AREA)
• Physical Education & Sports Medicine (AREA)
• Pulmonology (AREA)
• Neurosurgery (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Cardiology (AREA)
• Rheumatology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Pain & Pain Management (AREA)
• Nutrition Science (AREA)
• Endocrinology (AREA)
• Ophthalmology & Optometry (AREA)
• Emergency Medicine (AREA)
• Vascular Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Gastroenterology & Hepatology (AREA)
• Transplantation (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=42288162

Family Applications (4)

Family Applications After (3)

Country Status (9)

Cited By (24)

Families Citing this family (22)

Citations (3)

Family Cites Families (83)

• 2009
  • 2009-12-23 CA CA2772760A patent/CA2772760A1/en not_active Abandoned
  • 2009-12-23 CN CN201510081043.1A patent/CN104803986A/zh active Pending
  • 2009-12-23 US US13/141,545 patent/US20120122889A1/en not_active Abandoned
  • 2009-12-23 CN CN2009801569144A patent/CN102316735A/zh active Pending
  • 2009-12-23 JP JP2011543689A patent/JP2012513481A/ja active Pending
  • 2009-12-23 AU AU2009329879A patent/AU2009329879A1/en not_active Abandoned
  • 2009-12-23 EP EP09835866A patent/EP2381775A4/en not_active Withdrawn
  • 2009-12-23 WO PCT/US2009/069483 patent/WO2010075561A1/en not_active Ceased
  • 2009-12-23 EP EP15001699.6A patent/EP3000468A1/en not_active Withdrawn
  • 2009-12-23 BR BRPI0923126-9A patent/BRPI0923126A2/pt not_active IP Right Cessation
• 2013
  • 2013-09-20 US US14/033,176 patent/US9586880B2/en active Active
• 2014
  • 2014-11-13 JP JP2014230271A patent/JP6178777B2/ja not_active Expired - Fee Related
• 2016
  • 2016-01-26 HK HK16100821.7A patent/HK1212973A1/zh unknown
  • 2016-04-12 AU AU2016202262A patent/AU2016202262A1/en not_active Abandoned
  • 2016-09-30 HK HK16111463.7A patent/HK1223272A1/en unknown
• 2017
  • 2017-02-08 US US15/427,699 patent/US20170305824A1/en not_active Abandoned
• 2018
  • 2018-08-06 US US16/055,898 patent/US20190135718A1/en not_active Abandoned

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events